Pfizer Wins Remicade Patent Case Over J&J

Ruling in favor of Pfizer and Celltrion over Johnson & Johnson's (J&J) Janssen, District Court Judge Mark Wolf wrote Tuesday in his 104-page ruling that the “defendants are entitled to summary judgment of non-infringement of the '083 patent because Janssen has not produced sufficient evidence to prove that the scope of equivalents would not ensnare the prior art.”